| TSC2 |
|---|
| Gene | [TSC2](/genes/tsc2) |
| UniProt ID | [P49816](https://www.uniprot.org/uniprot/P49816) |
| Molecular Weight | 198 kDa |
| Subcellular Localization | Cytoplasm, lysosomal membrane |
| Protein Family | TSC family, GAP domain proteins |
| Disease | Tuberous sclerosis complex |
TSC2 (Tuberin) is a tumor suppressor protein that forms a heterodimeric complex with TSC1 (hamartin) to regulate mTORC1 signaling. The TSC2 gene encodes a 198 kDa protein with multiple functional domains. TSC2 mutations cause tuberous sclerosis complex (TSC), a genetic disorder characterized by benign tumors throughout the body, including the brain.
TSC2 contains several functionally important domains:
- N-terminal domain: TSC1-binding region
- GAP domain (Rhodanese homology domain): GTPase-activating protein function
- Transactivation domain: C-terminal region for transcriptional regulation
- Multiple phosphorylation sites: For regulation by kinases including AKT, AMPK, and GSK3β
The TSC1-TSC2 complex functions as a tumor suppressor by regulating mTORC1:
| Function |
Mechanism |
| GAP activity |
TSC2 activates GTP hydrolysis on Rheb, inhibiting mTORC1 |
| Complex stability |
TSC1 stabilizes TSC2 and facilitates its localization |
| Lysosomal recruitment |
Complex localizes to lysosomes for Rheb regulation |
The TSC complex is a critical regulator of cellular growth:
- Growth factor signaling: PI3K/AKT phosphorylates and inhibits TSC2
- Energy sensing: AMPK activates TSC2 during energy stress
- Nutrient sensing: Amino acids activate mTORC1 independently of TSC
mTORC1 regulates:
- Protein synthesis via S6K and 4E-BP1
- Autophagy inhibition
- Lipid synthesis
- Mitochondrial metabolism
TSC2 dysfunction may contribute to AD pathogenesis:
- mTOR dysregulation: Hyperactive mTORC1 impairs autophagy
- Protein clearance: Defective autophagic-lysosomal pathway
- Synaptic plasticity: Impaired long-term potentiation
- Tau pathology: mTOR regulates tau phosphorylation
- Autophagy impairment: TSC2/mTOR affects alpha-synuclein clearance
- Lysosomal function: TSC2 regulates lysosomal biogenesis
- Mitochondrial health: mTORC1 modulates mitochondrial dynamics
mTOR inhibitors (rapamycin, everolimus) show promise:
- Enhanced autophagy
- Reduced protein aggregation
- Improved cognitive function in models
¶ TSC and Neurological Features
Tuberous sclerosis complex includes:
- Epilepsy: Cortical tubers cause seizures
- Intellectual disability: Variable severity
- Autism spectrum disorders: Common comorbidity
- Brain tumors: Subependymal giant cell astrocytomas (SEGAs)
mTOR inhibitors for TSC:
- Everolimus: FDA-approved for SEGA and renal angiomyolipoma
- Sirolimus: Rapamycin for various TSC manifestations
- Topical formulations: For skin lesions
- Knockout mice: Tsc2 deletion recapitulates disease
- Organoids: Patient-derived brain organoids
- iPSC models: Neurons from TSC patients
Key regulatory mechanisms:
- Growth factors: Insulin, IGF-1 activate PI3K/AKT
- Energy status: AMPK senses low ATP
- Oxygen levels: Hypoxia induces TSC expression
- Amino acids: Rag GTPases bypass TSC
Key TSC2-interacting proteins:
- TSC1: Stabilizing partner
- Rheb: GAP substrate
- AMPK: Energy sensing
- AKT/PKB: Growth factor signaling
- GSK3beta: Wnt pathway cross-talk